☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Aleta Biotherapeutics
Aleta Biotherapeutics Reports First Patient Dosing with ALETA-001 in P-I/II Study for Treating Relapsed/Refractory B-Cell Malignan...
February 22, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.